Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …

Simple Summary The gold standard for detecting cancer and profiling tumors is tissue
biopsies. Despite this, tissue biopsies have been associated with many limitations leading to …

Predictive biomarkers of response are essential to effectively guide targeted cancer
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Abstract Background Interim results from IMvigor010 showed an overall survival (OS) benefit
for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …

Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung
cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the …

Purpose: Bladder preservation is a viable option for some patients with muscle-invasive
bladder cancer (MIBC), but an effective noninvasive biomarker test to accurately identify …

Simple Summary The aim of this review is to evaluate the present status of the use of cell-
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …